Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Hypoxia-Specific Drug Tirapazamine Does Not Abrogate Hypoxic Tumor Cells in Combination Therapy with Irinotecan and Methylselenocysteine in Well-Differentiated Human Head and Neck Squamous Cell Carcinoma A253 Xenografts

(2015) Arup Bhattacharya et al.   NEOPLASIA

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

(2010) Sreenivasulu Chintala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Double Immunohistochemical Staining Method for HIF-1α and its Regulators PHD2 and PHD3 in Formalin-fixed Paraffin-embedded Tissues

(2010) Mary M. Vaughan et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

(2009) Stefan Kaluz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Inhibition of Colon Cancer Growth by Methylselenocysteine-Induced Angiogenic Chemomodulation Is Influenced by Histologic Characteristics of the Tumor

(2009) Arup Bhattacharya et al.   Clinical Colorectal Cancer

The nuances of therapy

(2009) Lee M. Ellis et al.   NATURE

Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer Drugs

(2008) A. Bhattacharya et al.   CLINICAL CANCER RESEARCH

Selenium and anticarcinogenesis: underlying mechanisms

(2008) Matthew I Jackson et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Why does cytotoxic chemotherapy cure only some cancers?

(2008) Philip Savage et al.   Nature clinical practice. Oncology